HomeNewsBusinessSmall business credit worth Rs 2.32 lakh crore at highest risk of default: Cibil

Small business credit worth Rs 2.32 lakh crore at highest risk of default: Cibil

Small business credit of Rs 2.32 lakh crore is at the highest risk of default, and micro-enterprises having loan outstanding of less than Rs 10 lakh are the most vulnerable because of the COVID-19 pandemic

April 22, 2020 / 13:36 IST
Story continues below Advertisement

Small business credit of Rs 2.32 lakh crore is at the highest risk of default, and micro-enterprises having loan outstanding of less than Rs 10 lakh are the most vulnerable because of the COVID-19 pandemic, a credit information company said on Wednesday.

It can be noted that ever since the outbreak of the virus infections and the subsequent lockdown that is scheduled to last at least 40 days, concerns are being raised about the financial health of small businesses.

Story continues below Advertisement

In its study, TransUnion Cibil said, at present, the total outstanding amount of all financiers to small businesses having a credit outstanding of less than Rs 50 crore is Rs 17.94 lakh crore, representing 28 per cent of the total outstanding credit.

The bureau has launched an enhanced methodology to include enterprises having less than Rs 10 lakh outstanding as well to assess their health.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show